Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. by Raymond N Moynihan, Georga P E Cooke, Jenny A Doust, Lisa Bero, Suzanne Hill, Paul P Glasziou

“…<h4>Conclusions</h4>For the common conditions studied, a majority of panels proposed changes to disease definitions that increased the number of individuals considered to have the disease, none reported rigorous assessment of potential harms of that widening, and most had a majority of members disclosing financial ties to pharmaceutical companies. Please see later in the article for the Editors' Summary.…”
Get full text

Development of a neonatal Göttingen Minipig model for dose precision in perinatal asphyxia: technical opportunities, challenges, and potential further steps by Marina-Stefania Stroe, Lieselotte Van Bockstal, Allan Valenzuela, Miriam Ayuso, Karen Leys, Pieter Annaert, Pieter Annaert, Sebastien Carpentier, Anne Smits, Anne Smits, Karel Allegaert, Karel Allegaert, Karel Allegaert, Adrian Zeltner, Antonius Mulder, Chris Van Ginneken, Steven Van Cruchten

“…The conventional pig is proven to be a good translational model for PA, but pharmaceutical companies do not use it to develop new drug therapies. …”
Get full text

EFSPI/PSI working group on data sharing: accessing and working with pharmaceutical clinical trial patient level datasets – a primer for academic researchers by Rebecca Sudlow, Janice Branson, Tim Friede, David Morgan, Caroline Whately-Smith

“…Methods Patient level data access models of all major pharmaceutical companies were surveyed and recommendations made to guide academic researchers in the most efficient way through the process of requesting and accessing patient level data. …”
Get full text

Application of Natural Language Processing with Supervised Machine Learning Techniques to Predict the Overall Drugs Performance by Duygu İçen, Pius Marthın

“…With the wealthy information regarding user's satisfaction and experiences about a particular drug, pharmaceutical companies make the use of online drug reviews to improve the quality of their products. …”
Get full text

Retail of veterinary immunobiological preparations on the Ukrainian market of veterinary vaccines by I. V. Bushuieva, N. M. Borysenko

“…The purpose of the work is to determine the indicators of the peculiarities of the market of veterinary preparations; To carry out studies on the level of saturation and appropriate provision of the agricultural animals sector with veterinary drugs included in the List of Veterinary Immunobiological Drugs registered in Ukraine; to analyze the market of registered immunobiological drugs for medicinal forms; to research the market share of pharmaceutical companies – holders of registration certificates (Ukrainian and foreign) and companies – producers (Ukrainian and foreign) of this product; to summarize the dependence of the range of used vaccines for birds from their most frequent diseases in a particular farm and the general epizootic situation in the region. …”
Get full text

Identification of the molecular determinants of antagonist potency in the allosteric binding pocket of human P2X4 by Gaia Pasqualetto, Marika Zuanon, Andrea Brancale, Andrea Brancale, Mark T. Young

“…The P2X4 receptor in particular has attracted significant interest from pharmaceutical companies due to its physiological roles in neuropathic pain and modulation of vascular tone. …”
Get full text

Recommendations for Cost-Conscious Treatment of Basal Cell Carcinoma by Palak V. Patel, Jessica N. Pixley, Hannah S. Dibble, Steven R. Feldman

“…Treatment prices were obtained from the Medicare National Fee Schedule, GoodRx, and pharmaceutical companies. The American Academy of Dermatology’s (AAD) guidelines for treating BCC were used to develop recommendations for cost-reductive treatment. …”
Get full text

MODERN ONCO DRUG FOR INTERNAL USE by O. L. Orlova, L. L. Nikolaeva, L. A. Korol, M. V. Dmitrieva, A. P. Polozkova, A. V. Lantsova, I. D. Gulyakin, N. A. Oborotova

“…Oral dosage forms (DF) are most common due to the relative simplicity of their production, convenience of use, accuracy of dosing and high stability. Therefore, pharmaceutical companies often reproduce generics in the form of tablets and capsules for oral administration. …”
Get full text

Risky business: COVAX and the financialization of global vaccine equity by Felix Stein

“…Specifically, COVAX conflates public health risk and corporate financial risk, leading it to privilege concerns of pharmaceutical companies over those of most participating countries – especially low and lower-middle income countries (LICs and LMICs). …”
Get full text

Flu vaccination among patients with diabetes: motives, perceptions, trust, and risk culture - a qualitative survey by Pierre Verger, Aurélie Bocquier, Chantal Vergélys, Jeremy Ward, Patrick Peretti-Watel

“…Patients trusted their doctors strongly regardless of their SIV behaviour, but unvaccinated patients had little trust in the government and pharmaceutical companies. Some discordances were found between perceptions and behaviour (e.g., remaining vaccinated despite doubts about SIV effectiveness or remaining unvaccinated despite feelings of vulnerability towards influenza complication), suggesting the existence of some vaccine hesitancy among patients. …”
Get full text

Analysing the landscape for prescription to non-prescription reclassification (switch) in Germany: an interview study of committee members and stakeholders by Natalie J. Gauld

“…A range of enablers and barriers emerged that influence reclassification including effects on the committee and process, or the desire of pharmaceutical companies to pursue reclassifications. Enabling market factors included the large population and a culture of self-medication. …”
Get full text

Drivers of Antibiotic Use in Poultry Production in Bangladesh: Dependencies and Dynamics of a Patron-Client Relationship by Abdullah Al Masud, Emily Kate Rousham, Mohammad Aminul Islam, Mohammad Aminul Islam, Mahbub-Ul Alam, Mahbubur Rahman, Abdullah Al Mamun, Supta Sarker, Muhammad Asaduzzaman, Muhammad Asaduzzaman, Leanne Unicomb

“…This paper aims to describe dependencies and relationships between different actors within unregulated broiler poultry production systems to understand the social and contextual determinants of antibiotic use in low-resource settings.Methods: We used a cross-sectional qualitative design including in-depth interviews among purposefully selected commercial poultry farmers (n = 10), poultry dealers (n = 5), sales representatives of livestock pharmaceutical companies (n = 3) and the local government livestock officer as a key-informant (n = 1). …”
Get full text

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness by Melanie Lindenberg, Valesca Retèl, Maartje Rohaan, Joost van den Berg, John Haanen, Wim van Harten

“…For six of these scenarios the cost-effectiveness was calculated: “Commercialization of TIL production” (the price was assumed to be 3 times the manufacturing costs in the academic setting) (−€51,550), “Pharmaceutical companies lowering the prices of ipilimumab” (€11,420), “Using TIL-therapy combined with ipilimumab” (−€10,840), “Automatic TIL production” (€22,670), “TIL more effective” (€23,270), “Less Interleukin-2” (€20,370). …”
Get full text

N-(4-Methoxyphenyl)Pentanamide, a Simplified Derivative of Albendazole, Displays Anthelmintic Properties against the Nematode Toxocara canis by Taís C. Silva, Ana C. Mengarda, Bruna L. Lemes, Susana A. Z. Lescano, Dalete Christine S. Souza, João Henrique G. Lago, Josué de Moraes

“…Pharmacokinetic, drug-likeness, and medicinal chemistry friendliness studies demonstrated an excellent drug-likeness profile for N-(4-methoxyphenyl)pentanamide as well as an adherence to major pharmaceutical companies’ filters. Collectively, the results of this study demonstrate that the molecular simplification of albendazole to give N-(4-methoxyphenyl)pentanamide may be an important pipeline in the discovery of novel anthelmintic agents. …”
Get full text

The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya by Amin, A, Zurovac, D, Kangwana, B, Greeenfield, J, Otieno, D, Akhwale, W, Snow, R

“…Reasons included: lack of clarity on sustainable financing of an expensive therapeutic for a common disease, a delay in release of funding, a lack of comparative efficacy data between AL and amodiaquine-based alternatives, a poor dialogue with pharmaceutical companies with a national interest in antimalarial drug supply versus the single sourcing of AL and complex drug ordering, tendering and procurement procedures. …”

The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. by Amin, A, Zurovac, D, Kangwana, B, Greenfield, J, Otieno, D, Akhwale, W, Snow, R

“…Reasons included: lack of clarity on sustainable financing of an expensive therapeutic for a common disease, a delay in release of funding, a lack of comparative efficacy data between AL and amodiaquine-based alternatives, a poor dialogue with pharmaceutical companies with a national interest in antimalarial drug supply versus the single sourcing of AL and complex drug ordering, tendering and procurement procedures. …”

Oxcarbazepine in the maintenance treatment of bipolar disorder. by Vasudev, A, Macritchie, K, Watson, S, Geddes, JR, Young, A

“…Authors, experts in the field and pharmaceutical companies were contacted requesting information on published or unpublished trials. …”

Tiagabine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability. by Young, A, Geddes, J, Macritchie, K, Rao, SN, Watson, S, Vasudev, A

“…Authors, other experts in the field and pharmaceutical companies were contacted for knowledge of suitable published or unpublished trials. …”

Completeness and consistency of primary outcome reporting in COVID-19 publications in the early pandemic phase: a descriptive study by Stoll, M, Lindner, S, Marquardt, B, Salholz-Hillel, M, DeVito, NJ, Klemperer, D, Lieb, K

“…In this sample, complete primary outcome reporting occurred more frequently in trials with vs. without involvement of pharmaceutical companies (76% vs. 45%), and in RCTs vs. other study designs (68% vs. 49%). …”

Evaluation of an In Silico Cardiac Safety Assay: Using Ion Channel Screening Data to Predict QT Interval Changes in the Rabbit Ventricular Wedge by Beattie, K, Luscombe, C, Williams, G, Munoz−Muriedas, J, Gavaghan, D, Cui, Y, Mirams, G

“…<h3>Introduction</h3> Drugs that prolong the QT interval on the electrocardiogram present a major safety concern for pharmaceutical companies and regulatory agencies. Despite a range of assays performed to assess compound effects on the QT interval, QTprolongation remains a major cause of attrition during compound development. …”